"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A1,US 2023/0241363 A1,173-295-688-936-266,2023-08-03,2023,US 202118004858 A,2021-07-09,US 202118004858 A;;US 202063049695 P;;US 2021/0041043 W,2020-07-09,SYSTEMS AND METHODS FOR A HYDROPHILIC CATHETER INTRODUCTION SYSTEM,Various embodiments of a hydrophilic catheter introduction system for improved insertion of a shunt catheter are disclosed herein. The catheter introduction system includes an introducer sheath defining an inner surface that includes a hydrophilic coating to aid in passage of a catheter through the introducer sheath. Evaluation of the catheter introduction system with respect to other catheter introduction systems resulted in a significant decrease in average catheter threading time.,DIGNITY HEALTH,FARBER S HARRISON;;DUCRUET ANDREW,DIGNITY HEALTH (2023-01-10),https://lens.org/173-295-688-936-266,Patent Application,yes,0,0,2,2,0,A61M25/0662;;A61M2025/0047;;A61M25/0045;;A61M27/002;;A61M25/0009;;A61M25/0009;;A61M25/0111;;A61M27/006;;A61M2025/0047;;A61M2025/0681;;A61M2210/1017,A61M27/00;;A61M25/00;;A61M25/01,,0,0,,,,PENDING
2,WO,A1,WO 2022/011230 A1,003-820-105-383-064,2022-01-13,2022,US 2021/0041043 W,2021-07-09,US 202063049695 P,2020-07-09,SYSTEMS AND METHODS FOR A HYDROPHILIC CATHETER INTRODUCTION SYSTEM,Various embodiments of a hydrophilic catheter introduction system for improved insertion of a shunt catheter are disclosed herein. The catheter introduction system includes an introducer sheath defining an inner surface that includes a hydrophilic coating to aid in passage of a catheter through the introducer sheath. Evaluation of the catheter introduction system with respect to other catheter introduction systems resulted in a significant decrease in average catheter threading time.,DIGNITY HEALTH,FARBER S HARRISON;;DUCRUET ANDREW,,https://lens.org/003-820-105-383-064,Patent Application,yes,4,0,2,2,0,A61M25/0662;;A61M2025/0047;;A61M25/0045;;A61M27/002;;A61M25/0009;;A61M25/0009;;A61M25/0111;;A61M27/006;;A61M2025/0047;;A61M2025/0681;;A61M2210/1017,A61M25/02,,0,0,,,,PENDING
3,WO,A2,WO 2008/033285 A2,040-557-794-521-202,2008-03-20,2008,US 2007/0019605 W,2007-09-07,US 84504806 P,2006-09-15,DELIVERY OF DOUBLE-STRANDED RNA INTO THE CENTRAL NERVOUS SYSTEM,"The present invention provides for compositions and methods for in vivo delivery of a cell-permeable complex to cells of the central nervous system, wherein the cell-permeable complex decreases the level of a functional target protein encoded by a target mRNA molecule. In preferred embodiments of the invention, the cell-permeable complex comprises an siRNA nucleic acid molecule operably linked to a cell-penetrating peptide, wherein the cell-penetrating peptide facilitates transport of the cell-permeable complex across both the blood brain barrier and cell membrane of a target cell. The methods of the invention further encompass the utilization of convection-enhanced delivery methods such as intracerebral clysis (ICC) to deliver the cell-permeable complex to the target cells of the central nervous system.",TRUSTEES OF CULUMBIA UNIVERSIT;;TROY CAROL M;;CONNOLLY E SANDER;;PRUNELL GISELLE F;;DUCRUET ANDREW F,TROY CAROL M;;CONNOLLY E SANDER;;PRUNELL GISELLE F;;DUCRUET ANDREW F,,https://lens.org/040-557-794-521-202,Patent Application,yes,0,17,3,3,23,C12N15/111;;C12N15/113;;C12N2310/14;;C12N2310/3513;;C12N2320/32;;C12N15/111;;C12N2310/3513;;C12N2320/32;;C12N2310/14;;C12N15/113,H04Q5/24,,0,0,,,,PENDING
4,WO,A3,WO 2008/033285 A3,088-047-970-625-919,2009-04-16,2009,US 2007/0019605 W,2007-09-07,US 84504806 P,2006-09-15,DELIVERY OF DOUBLE-STRANDED RNA INTO THE CENTRAL NERVOUS SYSTEM,"The present invention provides for compositions and methods for in vivo delivery of a cell-permeable complex to cells of the central nervous system, wherein the cell-permeable complex decreases the level of a functional target protein encoded by a target mRNA molecule. In preferred embodiments of the invention, the cell-permeable complex comprises an siRNA nucleic acid molecule operably linked to a cell-penetrating peptide, wherein the cell-penetrating peptide facilitates transport of the cell-permeable complex across both the blood brain barrier and cell membrane of a target cell. The methods of the invention further encompass the utilization of convection-enhanced delivery methods such as intracerebral clysis (ICC) to deliver the cell-permeable complex to the target cells of the central nervous system.",TRUSTEES OF CULUMBIA UNIVERSIT;;TROY CAROL M;;CONNOLLY E SANDER;;PRUNELL GISELLE F;;DUCRUET ANDREW F,TROY CAROL M;;CONNOLLY E SANDER;;PRUNELL GISELLE F;;DUCRUET ANDREW F,,https://lens.org/088-047-970-625-919,Search Report,yes,2,0,3,3,23,C12N15/111;;C12N15/113;;C12N2310/14;;C12N2310/3513;;C12N2320/32;;C12N15/111;;C12N2310/3513;;C12N2320/32;;C12N2310/14;;C12N15/113,A61K31/70;;A61K38/00,,2,2,055-858-494-487-00X;;008-891-144-845-372,16554356;;10.1124/jpet.105.097139;;10.1074/jbc.m205167200;;12097334,"MICHAELIS ET AL.: ""Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain."", J. PHARMACOL. EXP. THER., vol. 317, no. 3, June 2006 (2006-06-01), pages 1246 - 1253, XP002451305, DOI: doi:10.1124/jpet.105.097139;;TROY ET AL.: ""Mechanisms of p75-mediated Death of Hippocampal Neurons."", J. BIOL. CHEM., vol. 277, no. 37, 13 September 2002 (2002-09-13), pages 34295 - 34302",PENDING
5,US,A1,US 2009/0280058 A1,137-410-957-433-655,2009-11-12,2009,US 39747809 A,2009-03-04,US 39747809 A;;US 2007/0019605 W;;US 84504806 P,2006-09-15,Delivery Of Double-Stranded RNA Into The Central Nervous System,"The present invention provides for compositions and methods for in vivo delivery of a cell-permeable complex to cells of the central nervous system, wherein the cell-permeable complex decreases the level of a functional target protein encoded by a target mRNA molecule. In preferred embodiments of the invention, the cell-permeable complex comprises an siRNA nucleic acid molecule operably linked to a cell-penetrating peptide, wherein the cell-penetrating peptide facilitates transport of the cell-permeable complex across both the blood brain barrier and cell membrane of a target cell. The methods of the invention further encompass the utilization of convection-enhanced delivery methods such as intracerebral clysis (ICC) to deliver the cell-permeable complex to the target cells of the central nervous system.",TROY CAROL M;;CONNOLLY SANDER E;;PRUNELL GISELLE F;;DUCRUET ANDREW F,TROY CAROL M;;CONNOLLY SANDER E;;PRUNELL GISELLE F;;DUCRUET ANDREW F,THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (2009-04-21),https://lens.org/137-410-957-433-655,Patent Application,yes,11,13,3,3,23,C12N15/111;;C12N15/113;;C12N2310/14;;C12N2310/3513;;C12N2320/32;;C12N15/111;;C12N2310/3513;;C12N2320/32;;C12N2310/14;;C12N15/113,A61K38/00;;A61K51/00;;A61K38/54,424/1.69;;514/2;;424/94.3,1,1,016-338-240-406-114,pmc6730191;;10.1523/jneurosci.3643-04.2004;;15537872,"Davidson et al (The Journal of Neuroscience, 2004, 24(45):10040-10046)",DISCONTINUED
